دورية أكاديمية
Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties.
| العنوان: | Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties. |
|---|---|
| المؤلفون: | Zheng Zhou, Jia Guo, Brian Hetrick, Sameer Tiwari, Amrita Haikerwal, Yang Han, Vincent C Bond, Ming B Huang, Marie K Mankowski, Beth A Snyder, Priscilla A Hogan, Savita K Sharma, Dennis C Liotta, Terry-Elinor Reid, Lawrence J Wilson, Yuntao Wu |
| المصدر: | PLoS Pathogens, Vol 20, Iss 8, p e1012448 (2024) |
| بيانات النشر: | Public Library of Science (PLoS), 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Immunologic diseases. Allergy LCC:Biology (General) |
| مصطلحات موضوعية: | Immunologic diseases. Allergy, RC581-607, Biology (General), QH301-705.5 |
| الوصف: | The chemokine co-receptors CXCR4 and CCR5 mediate HIV entry and signal transduction necessary for viral infection. However, to date only the CCR5 antagonist maraviroc is approved for treating HIV-1 infection. Given that approximately 50% of late-stage HIV patients also develop CXCR4-tropic virus, clinical anti-HIV CXCR4 antagonists are needed. Here, we describe a novel allosteric CXCR4 antagonist TIQ-15 which inhibits CXCR4-tropic HIV-1 infection of primary and transformed CD4 T cells. TIQ-15 blocks HIV entry with an IC50 of 13 nM. TIQ-15 also inhibits SDF-1α/CXCR4-mediated cAMP production, cofilin activation, and chemotactic signaling. In addition, TIQ-15 induces CXCR4 receptor internalization without affecting the levels of the CD4 receptor, suggesting that TIQ-15 may act through a novel allosteric site on CXCR4 for blocking HIV entry. Furthermore, TIQ-15 did not inhibit VSV-G pseudotyped HIV-1 infection, demonstrating its specificity in blocking CXCR4-tropic virus entry, but not CXCR4-independent endocytosis or post-entry steps. When tested against a panel of clinical isolates, TIQ-15 showed potent inhibition against CXCR4-tropic and dual-tropic viruses, and moderate inhibition against CCR5-tropic isolates. This observation was followed by a co-dosing study with maraviroc, and TIQ-15 demonstrated synergistic activity. In summary, here we describe a novel HIV-1 entry inhibitor, TIQ-15, which potently inhibits CXCR4-tropic viruses while possessing low-level synergistic activities against CCR5-tropic viruses. TIQ-15 could potentially be co-dosed with the CCR5 inhibitor maraviroc to block viruses of mixed tropisms. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1553-7366 1553-7374 |
| Relation: | https://doaj.org/toc/1553-7366; https://doaj.org/toc/1553-7374 |
| DOI: | 10.1371/journal.ppat.1012448 |
| URL الوصول: | https://doaj.org/article/876c83ec1d1e47f8a72082ba070ecf97 |
| رقم الأكسشن: | edsdoj.876c83ec1d1e47f8a72082ba070ecf97 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 15537366 15537374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1012448 |